Envonalkib is a synthetic small-molecule anaplastic lymphoma kinase (ALK) inhibitor developed for targeted oncology applications. It is also known as TQ-B3139. Envonalkib belongs to the kinase inhibitor class and has been investigated particularly in ALK-positive non-small cell lung cancer (NSCLC).
Envonalkib is an orally active compound designed to inhibit ALK signaling, including activity against certain ALK variants associated with resistance to earlier ALK inhibitors. Research data also describe activity against c-MET.
Envonalkib is a targeted anticancer compound belonging to the ALK tyrosine kinase inhibitor class. Its chemical structure contains two defined stereocenters and incorporates a substituted bipyridine core.
The compound has the molecular formula C₂₄H₂₆Cl₂FN₅O₂ and molecular weight 506.40 g/mol. Its CAS Registry Number is 1621519-26-3.
Swapnroop Drugs and Pharmaceuticals provides Envonalkib for qualified pharmaceutical manufacturing, formulation development, oncology research and pharmaceutical sourcing requirements.
Envonalkib is a specialized targeted oncology API relevant to ALK inhibitor research and development.
Envonalkib inhibits ALK tyrosine kinase activity. Published research-product data report inhibitory activity against wild-type ALK as well as ALK resistance-associated variants including L1196M and G1269S.
The compound has also been described as having activity against c-MET, providing additional relevance for research into kinase signaling and resistance mechanisms.
Envonalkib is associated with:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150°C – 154°C |